^
Association details:
| Biomarker: | ATP1B1-NRG1 fusion |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
NRG1 fusion -positive gastrointestinal tumours: Afatinib as a novel potential treatment option
Excerpt:
WGTA revealed ATP1B1 -NRG1 fusion (exon 3 of ATP1B1 with exon 2 of NRG1), leading to increased NRG1 expression and potential susceptibility to afatinib.
